Drugs / VRVg-2
VRVg-2
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT03145766 | Apr 2017 → Jan 2018 | rabies | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT01930357 | Sep 2013 → Aug 2014 | rabies | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT04594551 | Oct 2020 → Jun 2021 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT04478084 | Aug 2020 → Mar 2022 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT04127786 | Oct 2019 → Mar 2020 | rabies | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT03965962 | Jul 2019 → Dec 2020 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRVg-2 | “Group 1: VRVg-2 + HRIG” NCT04594551 ↗ |
| Known as | Purified Vero Rabies Vaccine Serum Free | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01930357 ↗ |
| Known as | PVRV-NG | “A serum-free, highly purified Vero rabies vaccine (PVRV-NG) has been developed with no animal or human components and low residual DNA content.” PMID 35906106 ↗ Jul 2022 |
| Known as | VRVg | “Participants will receive receive 3 vaccinations of Purified Vero Rabies Vaccine Serum Free (VRVg)” NCT01930357 ↗ |
| Modality | Vaccine | “A serum-free, highly purified Vero rabies vaccine (PVRV-NG) has been developed with no animal or human components and low residual DNA content.” PMID 35906106 ↗ Jul 2022 |
| Route | Intramuscular | “0.5 mL, Intramuscular (Day 0, Day 7 and Day 28).” NCT01930357 ↗ |